RGNXHIGH SIGNALFINANCIAL10-K

RGNX shows massive revenue growth (+678%) but faces severe balance sheet deterioration with stockholders' equity plummeting 60% and total liabilities surging 70%.

The dramatic increase in liabilities alongside the collapse in stockholders' equity suggests potential financial distress or major debt restructuring. While revenue growth is impressive, the company's financial foundation has weakened substantially, raising concerns about liquidity and long-term viability.

Comparing 2026-03-05 vs 2025-03-13View on EDGAR →
FINANCIAL ANALYSIS

Revenue exploded from $1.3M to $10.4M (+678%) and operating losses improved significantly (-$233M to -$161M), indicating stronger business momentum. However, the balance sheet tells a troubling story with stockholders' equity crashing 60% to just $103M while total liabilities ballooned 70% to $350M, and cash declined 40% to $35M. The combination of deteriorating equity position, massive liability increases, and shrinking cash reserves creates significant financial risk despite operational improvements.

FINANCIAL STATEMENT CHANGES
Revenue
P&L
+677.9%
$1.3M$10.4M

Strong top-line growth of 677.9% — accelerating demand or successful expansion into new markets.

Interest Expense
P&L
-70.5%
$23.3M$6.9M

Interest expense declined — debt repayment or refinancing at lower rates improving earnings quality.

Total Liabilities
Balance Sheet
+69.8%
$206.3M$350.3M

Liabilities grew 69.8% — significant increase in debt or obligations, assess impact on financial flexibility.

Stockholders Equity
Balance Sheet
-60.4%
$259.7M$102.7M

Equity declined sharply — large losses, buybacks, or write-downs reducing book value significantly.

Cash & Equivalents
Balance Sheet
-40.1%
$57.5M$34.5M

Cash declined 40.1% — significant cash burn or deployment; verify adequacy of remaining liquidity runway.

Operating Income
P&L
+30.9%
-$233.3M-$161.2M

Operating leverage kicking in — revenue growth outpacing cost growth, a hallmark of scaling businesses.

Accounts Receivable
Balance Sheet
+28.8%
$20.5M$26.4M

Receivables grew 28.8% — monitor days sales outstanding for collection efficiency.

Operating Cash Flow
Cash Flow
+28.4%
-$173.1M-$124.0M

Operating cash flow grew 28.4% — strong conversion of earnings to cash, healthy business fundamentals.

Net Income
P&L
+14.6%
-$227.1M-$193.9M

Net income grew 14.6% — bottom-line growth signals improving overall business health.

Current Liabilities
Balance Sheet
+14.4%
$103.2M$118.1M

Current liabilities rose 14.4% — increased short-term obligations, watch current ratio.

LANGUAGE CHANGES
NEW — 2026-03-05
PRIOR — 2025-03-13
ADDED
As of February 27, 2026, there were 51,612,984 shares of the registrant s common stock, par value $0.0001 per share, issued and outstanding.
However, whether actual results and developments will conform with our expectations and predictions is subject to a number of risks, uncertainties, assumptions and other important factors, including, but not limited to: our ability to establish and maintain development partnerships, including our collaboration with AbbVie to develop and commercialize surabgene lomparvovec (sura-vec, ABBV-RGX-314) and our collaboration with Nippon Shinyaku Co., Ltd.
Our investigational gene therapies include: Surabgene lomparvovec (sura-vec, ABBV-RGX-314), which we are developing in collaboration with AbbVie to treat large patient populations impacted by wet age-related macular degeneration (wet AMD) and diabetic retinopathy (DR).
Since our inception, we have built and advanced multiple promising gene therapies into late-stage clinical development.
All of our gene therapies were built on our NAV Technology Platform.
+7 more — sign up free →
REMOVED
As of March 7, 2025, there were 50,086,138 shares of the registrant s common stock, par value $0.0001 per share, issued and outstanding.
We refer to commercial and investigational AAV vector-based gene therapies as AAV Therapeutics.
Our investigational AAV Therapeutics include: ABBV-RGX-314, which we are developing in collaboration with AbbVie to treat large patient populations impacted by wet age-related macular degeneration (wet AMD), diabetic retinopathy (DR) and other chronic retinal diseases characterized by loss of vision.
RGX-202, which we are developing to treat Duchenne muscular dystrophy (Duchenne), one of the most common fatal genetic disorders affecting children.
Since our inception, we have built and advanced multiple promising AAV Therapeutics into late-stage clinical development.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
PNRGHIGHPNRG achieved exceptional profitability improvement with net income surging 2,21...
2026-04-16
BNAIHIGHBNAI underwent a dramatic reverse stock split that reduced share count by 86% wh...
2026-04-16
LAKEHIGHLAKE's financial performance deteriorated significantly with operating losses wo...
2026-04-16
NXXTHIGHNextNRG experienced massive financial deterioration with operating losses explod...
2026-04-16
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →